Clinical trials: Neuromyelitis Optica Spectrum Disorders (NMOSD)
Neuromyelitis Optica, Devic's Disease
Autologous Transplant To End NMO Spectrum Disorder
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term…
- Conditions
- Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
- Trial name
- ATTEND (NCT03829566)
- Testing
- Rituximab, Cyclophosphamide, Mesna
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Neuromyelitis Optica Spectrum Disorders
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
- Trial name
- NCT06413654
- Testing
- B001
- Where
- 51 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Neuromyelitis Optica Spectrum Disease (NMOSD)
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study.
- Trial name
- NCT07592754
- Testing
- KSVCBD injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chinese PLA General Hospital
Neuromyelitis Optica Spectrum Disorder
Ofatumumab in AQP4-IgG Seropositive NMOSD
This is an open-label, single-arm, multicentre prospective pilot study to assess the efficacy and safety of ofatumumab in patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) in China.
- Trial name
- NCT05504694
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica, Autoimmune Diseases
Inectolizumab With Steroid Optimization in Newly Treated NMOSD
Title: Study of Inectolizumab Combined With Steroid Hormone Adjustment Strategies in Treatment-naive Patients With Neuromyelitis Optica Spectrum Disease Objective:This study aims to evaluate the steroid-sparing effect and safety…
- Conditions
- Neuromyelitis Optica, Autoimmune Diseases, Demyelinating Autoimmune Diseases, CNS
- Trial name
- NCT07159893
- Testing
- Inebilizumab + Rapid Steroid Tapering group, Inebilizumab + Standard Steroid Tapering group
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
MS (Multiple Sclerosis), NMO Spectrum Disorder (NMOSD)
Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder
The aim of this work is to do a detailed comparison between multiple sclerosis and Neuromyelitis Optica Spectrum Disorder due to delicate similarities between both diseases and wide rang of management and follow up of the patients
- Trial name
- NCT07304960
- Volunteers
- 100 people
- Sponsor
- Assiut University
NMO Spectrum Disorder
ACT with NMOSD Patients and Caregivers Pilot Study
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their…
- Trial name
- NCT05840055
- Testing
- Acceptance and Commitment Therapy
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Neuromyelitis Optica Spectrum Disorder Attack
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG).
- Trial name
- EASE-NMO (NCT06673394)
- Testing
- Complement protein C5 inhibitor, IVMP
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Trial name
- NCT07526493
- Testing
- Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Neuromyelitis Optica Spectrum Disorders, MOGAD
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in…
- Conditions
- Neuromyelitis Optica Spectrum Disorders, MOGAD, Multiple Sclerosis
- Trial name
- PoGe (NCT06865274)
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NMO Spectrum Disorder
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD)…
- Trial name
- NCT07377305
- Testing
- 10Hz tTIS (2-4mA) Intervention
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disease (NMOSD), Ripertamab
Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders
This clinical trial aims to evaluate the safety and efficacy of ripertamab in patients with neuromyelitis optica spectrum disorders (NMOSD). The key research objectives are as follows: 1.
- Trial name
- RIPERT-NMOSD (NCT07685678)
- Testing
- Ripertamab
- Volunteers
- 20 people
- Sponsor
- Zhongming Qiu
Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica
A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory disease of the central nervous system characterized by relapsing optic neuritis and longitudinal extensive transverse myelitis.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica, Devic's Disease
- Trial name
- NCT03062579
- Testing
- Tocilizumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fu-Dong Shi
NMO Spectrum Disorder, Azathioprine Adverse Reaction
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
Background: The pathogenesis of NMOSD has been linked to the cytokines interleukins (IL) -6, NOD-, LRR-and pyrin domain-containing 3 (NLRP3) and IL-18 that contribute to development of inflammatory reactionsmay.
- Trial name
- NCT05896605
- Testing
- Azathioprine
- Where
- China
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in…
- Trial name
- NCT02028884
- Testing
- Satralizumab, Baseline Treatment
- Where
- 40 sites in United States, France and 9 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
NMOSD is an autoimmune disease of the central nervous system that predominantly affects the spinal cord and optic nerves. The objectives of this study are to assess the efficacy and safety of FcRn antagonists (efgartigmod) for…
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
- Trial name
- FACT (NCT06497374)
- Testing
- Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone
- Volunteers
- 63 people
- Sponsor
- Tianjin Medical University General Hospital
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
- Trial name
- NCT07341828
- Testing
- CD20/BCMA-directed CAR-T cells
- Volunteers
- 15 people
- Sponsor
- Huashan Hospital
NMOSD
Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a nationwide observational study looking at how ravulizumab, a complement C5 inhibitor, affects blood biomarkers o sNfL and sGFAP in people with AQP4-antibody positive NMOSD.
- Trial name
- NCT06903130
- Testing
- Blood samples for sNfL and sGFAP levels
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- National and Kapodistrian University of Athens
NMOSD
Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
This study aims to characterize sex hormone alterations and their potential clinical significance in NMOSD patients from Southern China through comprehensive hormonal profiling.
- Trial name
- NMOSD (NCT07266051)
- Testing
- Sex hormone assay
- Where
- 5 sites in China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Xiamen Hospital of Traditional Chinese Medicine
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Interleukin-2 (IL-2) is an essential cytokine for T-cell proliferation. Low-dose IL-2 has been shown to increase the proportion of regulatory T cells (Tregs), negatively regulate effector T cells such as Th17 and Tfh cells, and…
- Trial name
- NCT07809724
- Testing
- IL-2 (interleukin 2)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital